Ipragliflozin, a sodium –glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

ConclusionsIpragliflozin treatment for 24 weeks resulted in reduced BW, mainly from fat mass loss. Muscle mass and bone mineral content were maintained. Further study is necessary to elucidate the long ‐term effects of ipragliflozin.

Source: Journal of Diabetes Investigation - January 21, 2019 Category: Endocrinology Authors: Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka ‐Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Osamu Sekine, Masahiro Yoshimura, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Hir Tags: Clinical Trial Source Type: research